NEFL and myeloid sarcoma: A recently published study of NFl concentrations in 10,133 blood samples, however, has provided extensive normative data [119], with accompanying age and BMI information, which will advance its potential as a biomarker in individual MS patients and even as a clinical trial endpoint.